Hemoglobin C trait is a rare blood disorder that affects a small number of people worldwide. It is caused by a mutation in the gene that codes for hemoglobin, the protein in red blood cells that carries oxygen throughout the body. This mutation results in the production of a slightly different form of hemoglobin, called hemoglobin C. People with hemoglobin C trait have no symptoms, but can pass the trait to their children. In this article, we will take a closer look at hemoglobin C trait and explore the potential risks associated with this rare disorder.
Hemoglobin C trait is a genetic condition caused by a mutation in the gene that codes for hemoglobin, the protein in red blood cells that carries oxygen throughout the body. This mutation results in the production of a slightly different form of hemoglobin, called hemoglobin C. People with hemoglobin C trait have no symptoms, but can pass the trait to their children. Hemoglobin C trait is most common in people of African, Mediterranean, and Middle Eastern descent. It is estimated that about 1 in 250 people of African descent have the trait, while about 1 in 500 people of Mediterranean and Middle Eastern descent have the trait.
Hemoglobin C trait is usually diagnosed through a simple blood test. If the test shows that the individual has hemoglobin C trait, they will not need any further treatment. However, it is important for people with hemoglobin C trait to be aware of the potential risks associated with the disorder. People with hemoglobin C trait should be monitored for any signs of anemia, which can be caused by a decrease in the number of red blood cells in the body. Anemia can lead to fatigue, shortness of breath, and paleness. If anemia is suspected, a doctor may recommend a blood transfusion to replace the missing red blood cells.
People with hemoglobin C trait are at an increased risk of developing a rare form of anemia called hemolytic anemia. This condition occurs when red blood cells are destroyed faster than they can be replaced, leading to a decrease in the number of red blood cells in the body. Hemolytic anemia can cause fatigue, shortness of breath, paleness, jaundice, and dark urine. If left untreated, this condition can be life-threatening. People with hemoglobin C trait are also at an increased risk of developing gallstones. Gallstones are hardened deposits of bile, a fluid produced by the liver to help digest fat. They can cause pain in the upper right side of the abdomen, nausea, and vomiting. In addition, people with hemoglobin C trait are at an increased risk of developing thalassemia, a group of inherited blood disorders that can cause anemia, fatigue, and other symptoms. Thalassemia can be life-threatening if left untreated.
Hemoglobin C trait is a rare blood disorder caused by a mutation in the gene that codes for hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People with hemoglobin C trait have no symptoms, but can pass the trait to their children. It is important for people with hemoglobin C trait to be aware of the potential risks associated with the disorder, including an increased risk of hemolytic anemia, gallstones, and thalassemia. If any of these conditions are suspected, a doctor should be consulted for diagnosis and treatment.
1.
A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.
2.
The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.
3.
Cancer diagnosis does not spur improvements to survivors' diets or eating habits
4.
According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.
5.
A garden can save your life
1.
Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy
2.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
3.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
4.
Cracking the Code of Subdural Hematomas: Modern Strategies for Optimal Care
5.
Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
4.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation